Journal of Andrology Download to Citation Manager
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Published-Ahead-of-Print June 20, 2007, DOI:10.2164/jandrol.106.002154
Journal of Andrology, Vol. 28, No. 6, November/December 2007
Copyright © American Society of Andrology
DOI: 10.2164/jandrol.106.002154

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
28/6/804    most recent
Author Manuscript (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shao, C.
Right arrow Articles by Shao, G.-X.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shao, C.
Right arrow Articles by Shao, G.-X.

Biphasic Effect of Androgens on Prostate Cancer Cells and Its Correlation With Androgen Receptor Coactivator Dopa Decarboxylase

CHEN SHAO*,||, YONG WANG{dagger},||, HONG-HONG YUE{ddagger}, YUN-TAO ZHANG*, CHANG-HONG SHI§, FAN LIU{dagger}, TING-YI BAO{dagger}, ZENG-YUE YANG{dagger}, JIAN-LIN YUAN* AND GUO-XING SHAO*

From the * Department of Urology, Xijing Hospital; {dagger} Department of Urology, Tangdu Hospital; {ddagger} Department of Clinical Immunology, Xijing Hospital; and § Department of Experimental Animal Center, the Fourth Military Medical University, Xi'an, China.

Correspondence to: Dr Yong Wang, Department of Urology, Tangdu Hospital, Fourth Military Medical University, Xi'an 710032, China (e-mail: dryongwangfmmu{at}yahoo.com.cn).


The aim of this study was to explore the mechanism underlying the dual effect of androgen on prostate cancer cells and further explore its correlation with dopa decarboxylase (DDC), an androgen receptor (AR) coactivator and a traditional neuroendocrine differentiation (NED) marker. Cell proliferation and cycling after treatment with synthetic nonmetabolizable androgen R1881 was determined by the MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide) method and flow cytometry. Differential gene expression was analyzed by cDNA microarrays. DDC expression during the dual effect of R1881 was further explored with microarray, quantitative reverse transcriptase–polymerase chain reaction (RT-PCR), Western blot, and enzyme activity assays. Proliferation of LNCaP cells was inhibited by 1 nM R1881 but stimulated by 0.1 nM R1881. Compared with the untreated cells, 320 (2.26%; 170 up-regulated, 150 down-regulated) and 4608 (32.65%; 2046 up-regulated, 2562 down-regulated) genes were found to be expressed differentially in the 1 nM and 0.1 nM R1881-treated cells, respectively. The results were partially confirmed by RT-PCR and Western blot. The DDC gene was down-regulated in the 1 nM R1881-treated cells and up-regulated in 0.1 nM R1881- and 30 nM hydroxyflutamide-treated cells. The enzymatic activity of DDC in the latter 2 groups was also strengthened. Meanwhile, the NED markers CgA and synaptophysin were not affected by these AR activators. R1881 had a dose-dependent biphasic effect on LNCaP cell proliferation. AR coactivator DDC was respectively down- and up-regulated in high and low concentrations of R1881. DDC up-regulation by exogenous AR activators is not accompanied by up-regulation of definitive NED markers.

     Key words: Neuroendocrine differentiation, methyltoenolone, cDNA microarray






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by The American Society of Andrology.